Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24973934 | 1.00 | RAB9A (0.38) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL18199502 | 0.90 | RAB9A (0.41) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL19864588 | 0.84 | RAB9A (0.43) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL15014593 | 0.82 | EPHX1 (0.48) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL15014614 | 0.82 | EPHX1 (0.48) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL18199497 | 0.81 | RAB9A (0.49) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL5067337 | 0.81 | RAB9A (0.49) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL24973923 | 0.81 | RAB9A (0.36) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL21502030 | 0.80 | KDM5A (0.32) | KDM5A | |
| SCHEMBL20340487 | 0.79 | RAB9A (0.36) | RAB9ACYP3A4HPGDCYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | RAB9A 1576/4885CYP3A4 1627/4885HPGD 34/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | RAB9A 1576/4885CYP3A4 1627/4885HPGD 34/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | RAB9A 1576/4885CYP3A4 1627/4885HPGD 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.